Intarcia Therapeutics Finds $50M

Emeryville-based Intarcia Therapeutics raised $50M in a Series BB round, the firm said yesterday. The funding will go towards development of the firm's lead therapeutic candidates for the treatment of hepatitis C and type 2 diabetes. The round was led by New Leaf Venture Partners, and also included Quilvest Ventures, New Enterprise Associates (NEA), Venrock Associates, Alta Partners, Omega Fund and Granite Global Ventures. James Niedel of New Leaf will join the firm's board as part of the funding. More information »